Adenoviral p53 (Ad-p53) for Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MultiVir Study Ad-p53-002)

The MultiVir Ad-p53-002 trial will be conducted to evaluate the safety and efficacy of investigational Ad-p53 in patients with recurrent HNSCC that have previously been treated with chemotherapy.

In this trial, Ad-p53 will be injected into recurrent HNSCC tumors. The Ad-p53 experimental treatment will be combined with an approved cancer therapy termed anti-PD-1 that may have complementary immune stimulating activity.

Studies performed in animal tumor models suggest that Ad-p53 may enhance the anti-tumor effects of anti-PD-1.